Arlington Capital Partners acquires majority interest in Everest Clinical Research Corporation

On Nov. 6, Arlington Capital Partners (“Arlington”) and Everest Clinical Research Corporation (“Everest”) completed a share purchase transaction whereby, among other things, Arlington acquired a majority interest in Everest.

Everest is a contract research organization providing a comprehensive suite of mission-critical clinical research services to the worldwide pharmaceutical, biotechnology and medical device industries across Phase I-IV trials. Headquartered in Toronto, Everest operates globally with offices in Canada, the U.S. and China.

Arlington is a Washington, DC-based private equity firm that is currently investing out of Arlington Capital Partners V, L.P., a US$1.7 billion fund. The firm has managed approximately US$4 billion of committed capital via five investment funds. Arlington is focused on middle market investment opportunities in growth industries including healthcare, government services and technology, aerospace and defense and business services and software.

DLA Piper represented Arlington Capital Partners with a team led by
Jeff Houle (Washington, DC),
Russel Drew (Toronto),

and which included partners
Thomas Pilkerton (Baltimore),

Paolo Morante (New York),
Christopher Mikson, M.D. (Philadelphia),

Michael Richards (Toronto),
Kevin Fritz (Toronto),

Sangeetha Punniyamoorthy (Toronto),
Alex Roberts (Toronto),

Veronica Monteiro (Edmonton),
Julia Kovacs (Washington, DC),

Qiang Li (Shanghai);
of counsel

Nia Brown (Washington, DC);
senior consultants

Allen Xu (Beijing),
Ying Li (Shanghai);

Fangfang Song (Beijing),

Yiyuan Zhang (Shanghai),
Frank Chen (Shanghai);

senior tax manager
Tina Xia (Hong Kong);

associates Mackenzie Clark (Toronto),
Matt Huddle (Baltimore),

Grace Latimer (Toronto),
Titus Totan (Toronto).

Blake, Cassels & Graydon LLP represented Everest Clinical Research Corporation with a team led by
Michael Stevenson
and which included

Michael Elder (Toronto),
Laura Gagnon (Toronto),

Shahrouz Hafez (Toronto)
Anna Abbott (Toronto).

Thorsteinssons LLP also represented Everest Clinical Research Corporation with a team led by
Brandon Wiener (Toronto),
Kyle Lamothe (Toronto).

Cozen O’Connor also provided advice as Everest’s U.S. counsel, with a team led by members
Steven Haas (Philadelphia),
Jay Dorsch (Philadelphia).

Catherine Guo, a partner of Anjie Law Firm in China, also advised Everest.

RBC Mid-Market Mergers and Acquisitions (Toronto office) acted as the exclusive financial advisor to Everest, with a team composed of Jeff Tone, Nisarg Shah, Jeff Miller and Tuhin Nair.